- Home
- ANTX vs IXHL Comparison
ANTX vs IXHL Comparison
Compare ANTX & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- IXHL
- Stock Information
- Founded
- ANTX 2017
- IXHL 2001
- Country
- ANTX United States
- IXHL Australia
- Employees
- ANTX 36
- IXHL N/A
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- IXHL
- Sector
- ANTX Health Care
- IXHL
- Exchange
- ANTX Nasdaq
- IXHL Nasdaq
- Market Cap
- ANTX 40.0M
- IXHL 39.2M
- IPO Year
- ANTX 2022
- IXHL N/A
- Fundamental
- Price
- ANTX $1.34
- IXHL $1.98
- Analyst Decision
- ANTX Hold
- IXHL
- Analyst Count
- ANTX 5
- IXHL 0
- Target Price
- ANTX $3.50
- IXHL N/A
- AVG Volume (30 Days)
- ANTX 1.0M
- IXHL 43.0K
- Earning Date
- ANTX 11-13-2024
- IXHL 11-14-2024
- Dividend Yield
- ANTX N/A
- IXHL N/A
- EPS Growth
- ANTX N/A
- IXHL N/A
- EPS
- ANTX N/A
- IXHL N/A
- Revenue
- ANTX N/A
- IXHL $86,000.00
- Revenue This Year
- ANTX N/A
- IXHL N/A
- Revenue Next Year
- ANTX N/A
- IXHL N/A
- P/E Ratio
- ANTX N/A
- IXHL N/A
- Revenue Growth
- ANTX N/A
- IXHL N/A
- 52 Week Low
- ANTX $0.87
- IXHL $0.95
- 52 Week High
- ANTX $22.22
- IXHL $12.68
- Technical
- Relative Strength Index (RSI)
- ANTX 72.02
- IXHL 42.07
- Support Level
- ANTX $0.98
- IXHL $1.96
- Resistance Level
- ANTX $1.46
- IXHL $2.20
- Average True Range (ATR)
- ANTX 0.08
- IXHL 0.24
- MACD
- ANTX 0.03
- IXHL -0.09
- Stochastic Oscillator
- ANTX 75.26
- IXHL 1.75
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.